Sarcoidosis with involvement of the paranasal sinuses - a retrospective analysis of 12 biopsy-proven cases by unknown
Kirsten et al. BMC Pulmonary Medicine 2013, 13:59
http://www.biomedcentral.com/1471-2466/13/59RESEARCH ARTICLE Open AccessSarcoidosis with involvement of the paranasal
sinuses - a retrospective analysis
of 12 biopsy-proven cases
Anne-Marie Kirsten1*, Henrik Watz1 and Detlef Kirsten2Abstract
Background: Extrapulmonary involvement by sarcoidosis is observed in about 30–40% of patients with sarcoidosis.
Little is known about the frequency and clinical characteristics of sinonasal sarcoidosis.
Methods: We retrospectively analyzed 12 cases of biopsy-proven sinonasal sarcoidosis. Patients were identified
from a patient population of 1360 patients with sarcoidosis at the Outpatient Clinic for Sarcoidosis and Rare Lung
Diseases at LungClinic Grosshansdorf, a tertiary care hospital for respiratory medicine.
Results: The most frequent signs and symptoms were nasal polyps (4 cases), epistaxis (3 cases), nasal crusts (8 cases)
and anosmia (5 cases). Pulmonary sarcoidosis of the patients was staged as stage I (n = 1) and stage II (n = 11) on chest
radiographs. Spirometry was normal in 11 patients. 7 patients had a diffusion capacity of the lung for carbon monoxide
of less than 90% of predicted. Other organs were affected in 8 patients. All patients received systemic corticosteroid
treatment and most patients received topical steroids. 5 patients received steroid sparing agents. Repeated sinus
surgery had to be performed in 4 patients.
Conclusions: Sinonasal involvement is a rare disease manifestation of sarcoidosis with a frequency slightly lower than
1% in our patient population. The clinical course of sinonasal sarcoidosis can be complicated by relapse despite
systemic immunosuppressive treatment and repeated sinus surgery.
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Sarcoidosis is a multisystem granulomatous disease com-
monly involving the lungs and the mediastinum. Sarcoid-
osis may not only affect the lungs and mediastinum but
also any other organ and extrapulmonary involvement is
observed in about 30–40% of patients with sarcoidosis [1].
The incidence of sarcoidosis in Germany has been esti-
mated by Scharkoff with about 10/100.000 per year [2]. A
survey among German patients with sarcoidosis organized
in the German Sarcoidosis self-help group revealed a fre-
quency of extrapulmonary involvement by sarcoidosis of
47.5% (but histologically proven in only 30%) [3].
Even though predilection of the respiratory tract by
sarcoidosis and extrapulmonary involvement of other* Correspondence: a.kirsten@pulmoresearch.de
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reproduction in any medium, provided the ororgans is frequently observed there is only limited data
available regarding the frequency of sinonasal involve-
ment [4]. As the symptoms of patients with sinonasal
sarcoidosis resemble the symptoms of chronic rhinitis
and chronic inflammatory rhinosinusitis like nasal ob-
struction, epistaxis, rhinorrhea, nasal crusts, anosmia or
facial pain sinonasal sarcoidosis might be an overlooked
disease manifestation [5].
In 1983 McCaffrey and McDonald reviewed the re-
cords of 2319 patients with sarcoidosis to determine the
incidence of nasal involvement. 17 patients were found
to have nasal lesions proven by biopsy to be of non-
caseating granulomatous inflammation [6].
Until now there are only very few data available regard-
ing frequency and clinical characteristics of sinonasal sar-
coidosis [7-13]. Here we report on 12 patients with
biopsy-proven sinonasal sarcoidosis who were treated in a
tertiary respiratory care setting.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population
We retrospectively analyzed 12 cases of biopsy-proven
sinonasal sarcoidosis. Patients were identified at the Out-
patient Clinic for Sarcoidosis and Rare Lung Diseases at
LungClinic Grosshansdorf, a tertiary care hospital for re-
spiratory medicine between 2007 and 2011. In total, 1360
patients with sarcoidosis were treated between 2007 and
2011, among these patients we observed about 500 patients
with extrapulmonary organ involvement. 24 patients were
identified by the treating pulmonologist (D.K.) to present
with symptoms of sinonasal disease. Only 12 of these 24
patients had a sinonasal biopsy taken for histopathological
confirmation of granulomatous inflammation and were in-
cluded in our retrospective analysis. The histopathological
confirmation in 12 patients was not performed due to ad-
equate response to topical steroid treatment, mild symp-
toms, or because patients refused ENT surgery. 4 out of 12
patients had a coincidence of outset of their sarcoidosis
and sinonasal involvement. In the remaining 8 patients
there was a period of time of 1–15 years between the initial
diagnosis of sarcoidosis and sinonasal manifestation.
According to German law an ethic approval was not
necessary due to the retrospective design of our investi-
gation and pseudonymization of patient data.
Results
Among the 12 patients with sinonasal sarcoidosis, 4 were
women and 8 were men. The mean age was 41 years
(Table 1). All patients were Caucasians. The most frequent
signs and symptoms were nasal polyps (4 cases), epistaxis
(3 cases), nasal crusts (8 cases) and anosmia (5 cases,
Table 2).
The levels of the angiotensin-converting enzyme
(ACE) in serum were elevated in 6 patients (> 52 Units/
Liter). The mean value of ACE in all patients was 72.9
Units/Liter (Table 1).
Pulmonary sarcoidosis of the patients was staged
according to chest X-rays based on the Scadding criteria
[14] as stage/group I (n = 1) and stage/group II (n = 11;
Table 2). Pulmonary biopsies (bronchial mucosa or
transbronchial biopsy) revealed pulmonary involvement
of sarcoidosis in all patients. In addition to sinonasal and
pulmonary involvement sarcoidosis affected other organs
in 8 patients (Table 2).Table 1 Demographics of the 12 patients
n 12




ACE (U/Liter) mean of all subjects (range) 72.9 (18–240)Spirometry was normal in the majority of our patients.
Only one patient had a combined restrictive-obstructive
ventilation abnormality (pulmonary involvement plus
marked endobronchial mucosal hypertrophy) resulting in
a forced vital capacity of 50% predicted (Table 2). 7 pa-
tients had a diffusion capacity of the lung for carbon mon-
oxide (DLCO) of less than 90% of predicted (Table 2).
None of the patients showed signs or symptoms of
acute Sarcoidosis (Löfgren’s syndrome; Table 1). CT scan
of the paranasal sinuses in 11 of 12 patients showed
signs of chronic sinus inflammation with mucosal thick-
ening and opacification of one or more sinuses (Figure 1).
The involvement of the maxillary sinuses was more fre-
quent than the involvement of the ethmoidal sinus or
frontal sinus in our patients (Table 2).
The systematic review of the histopathological reports
of the tissue biopsies revealed typical granulomatous in-
flammation in all cases (Table 2). In addition, in one pa-
tient the biopsies revealed eosinophiIic granulocytes
being sporadically present in sinonasal tissue without
any evidence of atopy or allergic asthma.
Treatment
Sinus surgery was performed in all patients. The main
reason for sinus surgery was histological confirmation of
the suspected paranasal sinus involvement of sarcoidosis.
In 4 patients sinus surgery had to be repeated - up to 6
times in one patient - because of persistent symptoms
despite systemic corticosteroid treatment.
Medical treatment with systemic (oral) corticosteroids
was initiated in all patients. Mean duration of cortico-
steroid treatment was 3 years (0.25-9 years). In addition,
most patients received topical, intranasal steroids and 5
patients received steroid sparing agents like azathioprine,
metotrexate, leflunomide or chloroquine. The indication
and the duration of systemic corticosteroid treatment as
well as the addition of steroid sparing agents were not
always triggered by sinonasal symptoms only, but also
by other organ involvements.
Discussion
Interestingly, the nasal mucosa involvement of sarcoidosis
is known since Boeck in 1905 (cited by Scadding [15]).
Furthermore, involvement of nasal sinuses has been de-
scribed by Schaumann in 1924 and 1926 (cited by
Boettger [16]). However, it is currently difficult to estimate
the exact prevalence of sinonasal involvement in patients
with sarcoidosis. We found 12 patients out of 1360 pa-
tients with sarcoidosis to have biopsy proven sinonasal
sarcoidosis. This frequency of slightly less than one per-
cent of patients being affected by sinonasal involvement is
in line with the reported frequency by McCaffrey and
McDonald [6]. The exact prevalence of sinonasal involve-
ment, however, might be clearly underestimated in



















1 yes no bone yes MSB yes 2 no no no no 99.0 91.0
2 yes no CNS yes MSB, ES, FS yes 2 no no yes no 115.0 68.0
3 yes yes spleen, liver yes MSB, ES, FS yes 1 yes yes yes yes 97.3 100.8
4 yes yes none yes MSB, ES, FS yes 2 no yes yes no 76.6 64.6
5 yes yes none yes MSB yes 2 no no no yes 109.0 90.0
6 yes yes none yes MSS, ES, FS yes 2 no no no no 125.9 101.1
7 yes yes none yes MSB, ES yes 2 n.a. n.a. n.a. n.a. 89.5 67.3
8 yes yes bone, kidney, spleen yes MSB, ES, FS yes 2 yes yes yes no 126.0 55.0
9 yes yes bone yes ES, FS yes 2 no yes yes yes 133.0 90.6
10 yes no skin n.a. n.a. yes 2 yes yes yes no 50.0 63.0
11 yes yes skin yes MSB yes 2 no no yes yes 87.6 59.4
12 yes yes spleen, liver yes MSB, ES, FS yes 2 no no yes no 80.7 66.5
N.A., not available; CT, computed tomography; * according to Scadding [reference 14]; FVC, forced vital capacity; DLCO, diffusion capacity for carbon monoxide; ** predicted values according to European Community




















Figure 1 CT scan (coronal) of biopsy-proven sinonasal
sarcoidosis affecting both maxillary sinuses.
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of sinonasal tissue is not regularly performed after
sinonasal surgery [17]. We found in total 24 patients with
symptoms of sinonasal disease in our study population.
The frequency of sarcoidosis of the upper respiratory
tractis estimated to be about 5% of patients with
established diagnosis of sarcoidosis, although upper airway
symptoms are more common in patients with sarcoidosis
[4,13]. Therefore, the incidence of sinonasal involvement
in sarcoidosis is generally believed to be clearly
underestimated [17]. Table 3 summarizes the reported fre-
quencies and clinical characteristics of patients with
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present study
2013 Retrospective Germany 1360 12
*1 race and characteristics refer to the whole population including 6 patients with p
*2 race and characteristics refer to the whole population including 25 patients with
n.a., not available.sarcoidosis clinics and respiratory departments of tertiary
care hospitals. It is difficult to find common characteristics
of these studies, but is seems that the reported frequencies
of sinonasal sarcoidosis are higher among study popula-
tions that involved African Americans.
In a recent case control stuy of 20 patients with
sinonasal sarcoidosis Aubart et al. showed that sinonasal
involvement preceded the diagnosis of sarcoidosis in the
majority of the patients [18], which is not in line with
our observation. In our case series the majority of pa-
tients developed sinonasal involvement after the initial
diagnosis of sarcoidosis.
CT scans of the paranasal sinuses were done in 11 of
12 patients. In our patients we noticed a predominance
of both maxillary sinuses. CT findings of mucosal thick-
ening and sinus opacification were seen frequently in
our patients, whereas other signs of chronic sinus in-
flammation like destruction, erosions or bone lesions
were not seen, but are described in the literature [7,19].
Granulomas or nodules are not always visible and con-
stitute a frequent and helpful diagnostic criterium of sar-
coidosis [7]. Interpretation of other CT features such as
opacification of paranasal sinuses, nasal cavities or in-
volvement of nasopharynx depend on the clinical con-
text and are nonspecific radiologic features.
Treatment of sinonasal sarcoidosis includes topical or
systemic steroids and sinonasal surgery [7,11,12,19]. Re-
sponse to treatment varies from complete remission to











































robable sinonasal sarcoidosis (i.e. no histology available).
probable sinonasal sarcoidosis (i.e. no histology available).
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dication for systemic therapy with corticosteroids was
driven by other organ involvements as well. We had one
patient, who had to undergo repeated sinus surgeries for
sinonasal sarcoidosis despite systemic and topical steroid
treatment, which indicates that sinonasal sarcoidosis is
not clinically trivial but a rather serious complication of
sarcoidosis. Relapse of sinonasal sarcoidosis and the
need for longterm systemic corticosteroid treatment has
been encountered as a clinical problem in case series be-
fore [12].
Interestingly, all of our patients with sinonasal sarcoid-
osis had pulmonary and lymph node involvement. Fur-
thermore, 8 of 12 patients had one or more additional
organ involvement of sarcoidosis. This is in line with re-
cent data demonstrating that multiorgan disease is com-
mon among patients with sinonasal sarcoidosis [4,7,12].
Pulmonary involvement according to the chest-X-ray-
grade of Scadding [14] was graded as type I and II in
our patients. This is consistent with the relatively mild
impairment of lung function in the majority of our
patients.
Conclusion
To conclude sinonasal involvement is a rare disease
manifestation of sarcoidosis. The key to the diagnosis of
sinonasal involvement in sarcoidosis is the clinical
awareness of this disease manifestation. Biopsy with
histopathological examination needs to be performed to
confirm the diagnosis. The clinical course of sinonasal
sarcoidosis can be complicated by relapse despite
longterm systemic immunosuppressive treatment and
repeated sinus surgery.
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